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ABSTRACT: 
Neurotrophins are critical signaling molecules for cells of the central nervous 
system, as they have the ability to regulate proliferation, differentiation, and 
apoptosis.  Neurotrophin expression can be influenced by sensory input, which 
has implications for both normal development of the central nervous system and 
remodeling that may occur in response to altered sensory input. We examined 
neurotrophin expression in the visual cortex in response to retinal degeneration 
as a model for Traumatic Brain Injury (TBI). We used a well-characterized mouse 
model system in which loss of function of a visual signaling molecule 
(phosphodiesterase 6β) causes retinal degeneration and loss of visual acuity in 
all mice by postnatal day (PND) 49. Using Q-PCR, we showed that expression of 
several neurotrophins, including BDNF, NT-3, and NGF was altered at the mRNA 
level in response to retinal degeneration. We also examined the protein 
expression levels of BDNF and NT-3 using western blotting. These analyses 
showed a decrease in BDNF protein levels at PND 49 in response to retinal 
degeneration, consistent with mRNA results; NT-3 protein levels did not reflect 
mRNA alterations that were seen in response to retinal degeneration, suggesting 
that NT-3 expression is regulated post-transcriptionally. The alterations in 
neurotrophin expression could have implications for remodeling in response to 
the loss of sensory input to the visual cortex, which can be related to TBI. 
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INTRODUCTION: 
 
TRAUMATIC BRAIN INJURY: 
Traumatic Brain Injury (TBI) currently affects approximately 3.2 to 5.3 million 
people in the United Sates (Finan, 2018). The Centers for Disease Control (CDC) 
define TBI as “Injury to head arising from blunt or penetrating trauma or from 
acceleration – deceleration forces that are associated with symptoms or signs 
attributable to the injury” (Thurman, et al., 1999). Signs and symptoms of TBI 
include decreased levels of consciousness, amnesia, skull fractures, diagnosed 
intracranial lesions, neurological and neuropsychological abnormalities, or death 
(Thurman, et al., 1999; Roozenbeek, et al., 2013). From the millions of people 
affected, TBI claims 52,000 lives per year in the United States alone (Faul, et al., 
2010). TBI is most commonly caused by events such as vehicle accidents, 
sports-related injuries, combat, physical abuse, or age-related accidents. There 
are several lasting medical issues surrounding TBI, including encephalopathy, 
Parkinson’s Disease, and diminished quality of life (Crane et al., 2016; Gardner 
et al., 2015). Overall, TBI causes a multitude of cognitive and physical 
interruptions that could possibly be reduced, if more thoroughly investigated. It is 
also important to note that the long-term effects of TBI have recently been 
examined and shown to have severely hazardous effects.  Because TBI is such a 
prevalent issue, it is important to investigate ways in which the brain reacts to 
trauma. 
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NEUROTROPHINS: 
Neurotrophins are protein growth factors that are involved in cell differentiation, 
proliferation, survival, and death. They are synthesized a proproteins, or pro-
neurotrophins, that are cleaved to give rise to mature proteins. Four different 
neurotrophins have been well-characterized in mammals, including, Neurotrophin 
– 3 (NT-3), Neurotrophin – 4 (NT-4), Nerve Growth Factor (NGF), and Brain-
Derived Neurotrophic Factor (BDNF). These neurotrophin proteins become 
especially important when brain injuries occur that cause a damaged network of 
brain cells. This is because the neurotrophins are involved in creating new neural 
connections and strengthening those that are already existing, as described 
below.  
 
BDNF: 
BDNF is linked to neuronal survival and function and is also highly expressed in 
hippocampal and cortical structures (Chao et al., 2006). BDNF is the 
neurotrophin has been found to be highly involved in synaptogenesis and neural 
connectivity, as well as the formation and maintenance of dendritic structure 
(Bing Hu and Cohen-Cory, 2005). Because of these roles involving brain 
plasticity, BDNF is of great interest in recovery from TBI. Mature BDNF has been 
shown to bind to a specific receptor called Tropomyosin receptor kinase B (TrkB) 
(Bramham and Messaoudi, 2005). When bound to its receptor, the BDNF-TrkB 
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complex will then serve as a docking site for second messengers aiding in the 
synaptic plasticity process (Bramham and Messaoudi, 2005). Research has also 
shown that these TrkB receptors are expressed in oligodendrocytes (Santi et al., 
2006). When BDNF binds to TrkB in oligodendrocytes, proliferation was 
promoted, causing the brain remodeling (Santi et al., 2006). 
 
NT-3: 
NT-3 is found in the hippocampus, cerebellum, and spinal cord (Koyama et al., 
2005). There are also other brain regions, known as sub-populations of neuronal 
cells, that constitutively produce NT-3 (Koyama et al., 2005).  Like BDNF, NT-3 
was determined to also be produced by astrocytes, which serves to convert 
resting astrocytes to reactive astrocytes (Mele et al., 2010, Koyama et al., 2005). 
This phenomenon poses an interest because astrocytes compose such a large 
percentage of brain cells, as well as play an important role in support of health 
and diseased brains. More information will be provided on astrocytes in later 
sections. Also, like BDNF, NT-3 has been linked to neuronal survival and function 
and is also highly expressed in cortical structures (Chao et al., 2006). NT-3 
function has also been connected to the responsibilities of reduction of neuronal 
cell death, regeneration of damaged neurons, and promotion of regeneration of 
the spinal cord, septum, and striatum (Koyama et al., 2005).  
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NGF: 
NGF is a secreted protein that can induce neurite outgrowth (Carleton et al., 
2018). The classic targets for NGF include the sensory and sympathetic neurons 
of the PNS (Oshima and Guroff, 1996). However, NGF is a hormone/growth 
factor, it is found in almost all locations in the brain and PNS, to support the 
growth of nerves (Chao et al., 2006). NGF was determined to be responsible for 
the transport of nutrients to nerves, encourages neurite growth, produces cellular 
hypotrophy, and increases expression of enzymes involved in neurotransmitter 
synthesis (Oshima and Guroff, 1996). NGF also mediates other activities such as 
memory, behavior, and survival of neurons in the central nervous system (CNS) 
when processed into mature NGF (Chao et al., 2006). When NGF is processed 
into its mature form, it is highly involved in cell survival mechanisms activated by 
tyrosine kinase receptor A (TrkA). 
 
NT-4: 
NT-4 was the last of the neurotrophins to have been characterized. It can be 
located in several areas of the brain but is heavily localized in the hippocampus 
and amygdala regions. Like NGF, NT-4 was found to mediate activities such as 
memory, behavior, and survival of neurons in the central nervous system (CNS) 
when processed into mature NT-4 (Chao et al., 2006). NT-4 also enhanced 
glutamatergic synaptic transmission in cultured hippocampal neurons (Xie et al., 
2000). Along with BDNF, mature NT-4 associates with the TrkB receptor. Studies 
have shown when the NT-4 gene was deleted, deficiencies in long-term memory 
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for contextual and auditory fear conditioning were observed (Xie et al., 2000). 
Fear conditioning is associated with the regions of the brain that strongly express 
NT-4, mainly the hippocampus. Another consequence of an NT-4 deficiency is a 
disruption of memory consolidation (Xie et al., 2000). NT-4 has been shown to be 
critically involved in activity-dependent, long-term synaptic plasticity (Xie et al., 
2000).   
 
PRO-NEUROTROPHINS AND PROPROTEIN CONVERTASES: 
All four of the neurotrophins are synthesized in their pro-form and must be 
activated by endoproteolytic cleavage. Proprotein convertases (PCs) comprise a 
family of subtilisin-like, eukaryotic, serine endoproteases (Seidah and Chretien, 
1999). These endoproteases work to activate a variety of proteins, including the 
aforementioned neurotrophins, growth factors, receptors, cell adhesion 
molecules, and metalloproteases (Bresnahan et al., 1990). Several PCs have 
been characterized, including furin, PACE4, PC5, PC7, and PC3 (Seidah and 
Chretien, 1999). PCs have also been shown to be expressed in several areas of 
the brain, allowing them a role in processing neurotrophins (Seidah et al., 1996). 
Each neurotrophin is cleaved by one or more of the PCs, either intracellularly, 
extracellularly, or both, to yield the mature neurotrophin. Significantly, when pro-
neurotrophins were not cleaved by the PCs, they retained biological activity, but 
function quite differently than the mature forms. Pro-neurotrophins are 
proapoptotic and can affect long tern potentiation in the brain through interactions 
with the p75NTR receptor (Jarvinen et al., 2010). The function of pro-
 
 
6 
neurotrophins versus that of mature forms are thus antagonistic, where pro-
neurotrophins promote apoptosis and mature neurotrophins promote 
differentiation and proliferation. This makes the expression of both PCs and 
neurotrophins significant and examining how this expression changes in 
response to TBI could have considerable importance. PC expression has been 
shown to change in response to retinal degeneration, with potential implications 
for neurotrophin activity; for example, pro-BDNF is known to be upregulated 
during early postnatal brain development, potentially increasing the amount of 
mature BDNF after PC processing (Jarvinen et al., 2010). However, it is unknown 
how levels of pro-BDNF are affected by TBI or how changes in PC expression 
impact BDNF function in response to TBI, making investigation into these areas 
potentially significant.    
 
Pro-NT3 is the precursor to mature NT-3. It has been established that pro-NT3 is 
primarily found in Müeller cells and photoreceptors in the brain (Shen et al., 
2013). The amount of pro-NT3 available is directly related to the availability, or 
upregulation, of both mature NT-3 and the p75NTR receptor. The increase in pro-
NT3 promotes degeneration of the healthy retina, which is part of photoreceptor 
homeostasis (Shen et al., 2013). Little is known about pro-NT3 and mature NT-3 
levels before, during, and after trauma to the brain. For this reason, investigation 
into NT-3 is of great importance. 
 
 
 
 
7 
SIGNALING: 
TBI, as well as the visual impairment process, cause significant brain remodeling 
to occur. Another way to describe brain remodeling is brain plasticity. Brain 
plasticity is the ability of different types of brain cells, like neurons and glial cells, 
to create new connections to promote brain remodeling. When a TBI occurs, 
brain remodeling is a key factor in regenerating healthy neural connections, and 
therefore, healthy brain activities. To promote brain plasticity, neurotrophins are 
released. The neurotrophins are unique for many reasons, one being they exert 
cellular effects through two different receptors, Trk (tyrosine kinase family 
receptors) and, as mentioned before, p75NTR (Chao et al., 2006). When mature 
neurotrophins bind to the Trk receptors, they activate them, which in turn 
regulates cell proliferation and survival, axonal and dendritic growth and 
remodeling, assembly of the cytoskeleton, membrane trafficking and fusion, and 
synapse formation and function (Bramham and Messaoudi, 2005).  Pro-
neurotrophins will bind to the p75NTR receptor to promote cell death pathways 
(Chao et al., 2006). As presented in Figure 1, once the neurotrophins are 
processed by the PCs, the mature neurotrophin will bind to their appropriate Trk 
receptor and promote cell proliferation and differentiation. Or, if they are not 
processed by PCs, the pro-neurotrophin will binds to the p75NTR receptor and 
promote apoptosis.  
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Figure 1: Proprotein Convertase Processing of Neurotrophins 
 
Figure 1: Flow chart of the proprotein convertase (PC) processing of pro-neurotrophins 
to give rise to mature neurotrophins, therefore increasing cell differentiation and 
proliferation. Pro-neurotrophins signal cell death. 
 
 
The neurotrophin-Trk complex will then serve as a docking site for second 
messengers aiding in the synaptic plasticity process (Bramham and Messaoudi, 
2005). Research has also shown that these Trk receptors are expressed in 
oligodendrocytes (Santi et al., 2006). When BDNF binds to TrkB in 
oligodendrocytes proliferation is promoted, causing the brain remodeling (Santi et 
al., 2006). NGF binds as a complex to a Trk receptor, specifically the TrkA 
receptor. This cell cell-survival is depicted in Figure 2 (Chao et al., 2006). 
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Figure 2: Trk Receptor Binding 
 
Figure 2: Trk receptor structure and the consequences of neurotrophin binding. 
Resultant signaling promotes cell differentiation, proliferation, and survival (Chao 
et al., 2006). 
 
Once the mature neurotrophins bind to the Trk receptor, the activated Trk 
receptors recruit adaptor proteins and effectors. At this point the adaptor 
proteins, Shc and FRS2, influence signal transduction and cross-talk, while the 
effectors, PI3K and PLC-g, are molecules that selectively bind to proteins to 
regulate biological activity. The two main pathways activated by neurotrophin 
binding to the Trk receptors are the PI3/Akt and Ras/Erk pathways (Chao et 
al.,2006). Both of these are well-characterized pathways that promote cell 
differentiation and survival. In contrast to mature neurotrophin binding to Trk 
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receptors, when pro-neurotrophins bind to the p75NTR, apoptosis is induced. In 
Figure 3 we see the pathways in which apoptosis is induced.  
 
Figure 3: p75NTR Receptor Binding 
 
 
Figure 3: Pro-neurotrophin binding to p75NTR receptor induces apoptotic 
pathways. (Kaplan and Miller, 2000) 
 
The binding of pro-neurotrophins to the p75NTR receptor engages several proteins 
and pathways. Most proteins involved in this process induce cell death or an exit 
from the cell cycle causing eventual cell senescence. These apoptotic pathways 
are induced by proteins SC-1, NRIF1, NRAGE. This will cause an increase in the 
level of cellular ceramide causing the JNK-p53-Bax pathway to activate and cause 
cell death (Kaplan and Miller, 2000).   
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TBI MOUSE MODEL: 
We have utilized a mouse model to investigate TBI for this study. According to a 
study by Finan called “Biomechanical Stimulation of Traumatic Brain Injury in the 
Rat,” a major reason for choosing a mouse model instead of another animal 
model, such as a rat, is because there is still a gap in TBI experimental data for 
producing traumatic brain injuries in the lab (Finan, 2018). To test the effects of 
TBI in a lab setting, visual impairment was selected to use as a model for brain 
trauma, rather than other methods that have proved crueler and give less 
consistent results. Mice with a nonsense mutation in their phosphodiesterase-6 
beta (Pde6b) gene will lose all sight by postnatal day (PND) 49. This is a 
naturally occurring mutation in the Pde6b subunit gene, which is expressed in rod 
photoreceptors and causes a disease called retinitis pigmentosa (Hart, el al., 
2005; Cornett et al., 2011). A functional Pde6b gene contributes to a 
heterotetrametric phosphodiesterase complex that regulates cytoplasmic cGMP 
levels in rod photoreceptors in response to light stimuli (Hart, el al., 2005). When 
the Pde6b subunit is mutated, there will be an elevated cGMP level because a 
permanent opening of the cGMP-gated cation channel (Figure 4) in the 
membrane of the rod photoreceptors (Hart, el al., 2005). This continuous opening 
in the cGMP-gates cation channel leading to apoptosis, causing blindness to 
occur (Hart, el al., 2005). Phenotyping has determined that this mutation 
produces a slow progression of retinal degeneration, causing total blindness in 
mice by PND 49, which is beneficial for lab studies (Hart, el al., 2005). Because 
the Pde6b- mutation destroys rod photoreceptors, the brain must react. This 
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reaction is known as remodeling. In a study performed by Cornett et al. (2011), 
Pde6b-, or retinal degeneration (RD), mice demonstrated glial plasticity based on 
mRNA data in the RD mice at PND 28 and 49, as well as significant changes in 
astrocyte densities (Cornett et al. 2011). Due to the occurrence of brain 
remodeling with the Pde6b- mutation, like that of TBI, it makes the RD mouse 
model a good fit for research on TBI.  Figure 4 is a pictorial representation of 
what occurs in the rod photoreceptors in RD mice. 
 
Figure 4: Pictorial Representation of the Pde6b- Mutation 
 
Figure 4: An explanation of the mechanism of the Pde6b- mutation. The left side 
of Figure 4 shows the layout of the rod photoreceptor. The right side of Figure 4 
is a detailed look into the mutation of the Pde6b- subunit of a rod photoreceptor. 
The mutation is labeled with a red “X”, which leaves the ion channel open, 
leading to increased cytoplasmic cGMP and eventual apoptosis (Fain, et al., 
2010.  
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BRAIN REGIONS AND CELL TYPES OF INTEREST: 
The complex nature of the brain has researchers looking into the many regions it 
possesses.  For this project, the focus is on part of the cerebral cortex called the 
visual cortex (VC). The VC is the part of the cerebral cortex that receives and 
processes sensory nerve impulses from the eyes. Mammalian visual systems 
establish visual pathways based on input received from the retina (Cornett et al., 
2011). These stimuli establish the correct visual pathways for sight (Cornett et 
al., 2011). In order to continue to shape the neural connections in the VC, a 
combination of spontaneous stimuli-evoked activities must perpetually occur 
(Cornett et al., 2011). In the developing mouse, normal neural circuitry is 
established by PND 35 (Cornett et al., 2011).  
 
The VC is comprised of different types of glial cells. Glial cells include several 
different types of neural cells including satellite cells, Schwann cells, 
oligodendrocytes, astrocytes, ependymoglia, and Müeller and Bergman glial 
cells. Glial cells, such as astrocytes and oligodendrocytes, are supportive cells to 
both the central nervous system (CNS) and peripheral nervous system (PNS). 
These support cells carry nutrients and provide protection to other neural cells, 
including neurons. Oligodendrocytes are known as the myelinating cells in the 
CNS (Michalski and Kothary, 2015). The myelination process is crucial to neuron 
survival and activity; without myelination, neurons cannot maintain ion gradients, 
and will therefore affect impulse ability and strength (Michalski and Kothary, 
2015). BDNF is found in many areas of the brain and is implicated in brain 
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plasticity and remodeling, as stated previously. Synaptic activity between 
neurons, including that from TBI, induces activity-dependent release of BDNF in 
cells (Kuczweski et al., 2009). This is important because BDNF is widely 
abundant in the hippocampus, amygdala, and cerebellum, and is mainly 
expressed in neurons, astrocytes, and is secreted by dendrites, and therefore 
promotes synaptic regeneration and survival (Kuczweski et al., 2009). One type 
of glial cell, astrocytes, are a type of specialized cell that outnumber neurons by 
over fivefold (Sofroniew and Vinters, 2010). Astrocytes are the most abundant 
population of glial cells, making up nearly half of human brain cells, and one-third 
of mice brains (Ge et al., 2012; Cahoy et al., 2008). These cells are critical to the 
regulation of synaptic connectivity and strength (Cahoy et al., 2008). Astrocytes 
function to mediate transport of waste products and nutrients between blood 
vessels and neurons, as well as modulate neuronal activity and synaptic 
transmission (Reuss, 2009). In the VC, astrocytes comprise approximately 28% 
of all cells and 60% of glial cells (Cornett et al., 2011). Early in post-natal 
development, astrocytes reach adult-like numbers and have roles in 
synaptogenesis, neural plasticity, and modification of neurotransmitter release 
(Cornett et al., 2011). Astrocytes are responsible for supporting oligodendrocytes 
by secreting BDNF and NT-3 once there are signs of white matter ischemic injury 
(Miyamoto et al., 2015). This means that BDNF and NT-3 promote proliferation 
and differentiation of oligodendrocyte precursor cells into lineage cells (Miyamoto 
et al., 2015). The neurotrophins from these astrocytes also help to restore myelin 
function in neurons (Miyamoto et al., 2015). For these reasons, levels of pro- and 
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mature neurotrophins can vary throughout astrocytes, oligodendrocytes, and 
neurons depending on the trafficking of these proteins and the availability of 
proprotein convertases (PCs), such as furin, as well as the level of TBI or visual 
impairment in this study. Glial cells are a major source of neurotrophins in 
healthy and distressed central and peripheral nervous systems (Reuss, 2009). 
Neurotrophins have an important role in the regulation of cellular repair 
processes after injury, degeneration, and demyelination in both the CNS and 
PNS (Reuss, 2009).  
 
Preliminary data indicated mature BDNF expression is decreased in RD mice, 
compared to normal wild-type mice. Western blotting was performed to 
determine the expression levels of BDNF in both WT and RD mice. Those tests 
were performed using the visual cortices of numerous mice. This preliminary 
examination established the groundwork for future work with neurotrophin 
production. Based on this information, it is hypothesized that pro-neurotrophin 
levels will increase in the damaged areas of the brain because of their role in 
apoptosis, while mature neurotrophins could increase in other brain areas to 
promote brain remodeling. Therefore, for this study, the following was examined: 
 
SPECIFIC AIMS: 
AIM 1: Determine mRNA levels of BDNF, NT-3, NT-4, and NGF from VC of mice 
throughout the process of normal vision to visual impairment. 
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AIM 2: Determine levels of pro-BDNF and mature BDNF from VC of mice 
throughout the process of normal vision to visual impairment. 
 
AIM 3: Determine levels of pro-NT3 and mature NT-3 in VC of mice throughout 
the process of normal vision to visual impairment. 
 
The Pde6b- mutation that causes visual impairment serves as a model for TBI, 
which is testable for differences in the levels of neurotrophins. Mice were 
observed throughout postnatal days 14, 28, and 49 to view changes in 
neurotrophin levels as visual impairment sets in due to the Pde6b- mutation. In 
this study NT-4, NGF, BDNF, and NT-3 at the mRNA level and NT-3 and BDNF 
at the protein level will be the main areas of interest. 
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METHODS AND MATERIALS: 
 
ANIMALS: 
All mice were housed individually in standard cages in colony rooms with a 12:12 
(LD) cycle, with food and water provided ad libitum. Animals were bred for the 
purpose of this study, and all protocols were approved by the University 
Committee on Use and Care of Animals (UCUCA) at the University of Michigan 
and Emmanuel College. Separate groups of mice were used for each phase of 
the experiment.  
 
This study utilized a commercially available (Jackson Laboratories; Stock 
#003257) transgenic mouse strain, FVB/N-Tg(GFAP-GFP-Mes/J (Zhuo et al., 
1997), hereafter called RD mice. The RD mouse has a naturally-occurring 
nonsense mutation in exon 7 of the phosphodiesterase 6 b subunit (Pde6b) gene 
(Pittler and Baehr, 1991) expressed in rod photoreceptors (Bowes, et al., 1990). 
This causes cGMP levels to accumulate (Farber and Lolley, 1974) and leads to a 
moderate rate of retinal degeneration that occurs in several well-defined stages 
(Marc et al., 2003).  
 
An appropriate behavioral control for the RD mice is the congenic mouse strain, 
FVB.129P2-Pde6b+Tyrc-ch/AntJ, hereafter called WT mice (Jackson Laboratories; 
Stock #004828). This strain originated on a FVB;129P2 background and is 
homozygous for the 129P2/OlaHsd wildtype Pde6b allele. Backcrossed for least 
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11 generations on the FV background, WT mice do not show any evidence of 
retinal degeneration.  
 
VERIFICATION OF PDE6b- MUTATION: 
To begin, the difference between the WT mice and the RD mice had to be 
established. A simple test was used to verify the Pde6b- mutation. At PND 21, 
28, 35, 42, and 49, the Pde6b- and WT mice were lowered onto sand paper of 
varying grade (smooth, medium, and coarse). Mice were held by the tail and 
lowered down to a surface of sandpaper, where they would splay legs (or not) 
before impact. WT mice would splay legs while by PND 49 RD mice would not, 
therefore demonstrating visual impairment. 
 
RNA EXTRACTION AND cDNA SYNTHESIS: 
Tissue from the visual cortices was removed from normal and RD mice at 
different developmental time points (post-natal days 14, 28, and 49).  Total RNA 
was extracted from the tissue using the PureLink RNA Mini kit (Life 
Technologies; Carlsbad, CA). The Superscript III kit (Life Technologies) was 
used as a template for cDNA synthesis. The cDNA was used for quantitative 
real-time PCR as described below. 
 
QUANTITATIVE REAL-TIME PCR: 
Primers specific for the amplification of sequences coding for mouse BDNF, NT-
3, NGF, NT-4, and mouse glyceraldehyde-3-phosphate dehydrogenase 
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(GAPDH; used as a reference gene) were obtained from Qiagen (Valencia, CA).  
Quantitative Real-Time PCR was done using the RT2 SYBR Green Mastermix 
(Qiagen).  Reaction volumes and cycling conditions were set up according to the 
instructions provided by Qiagen.  Amplification was done using a Mastercycler ep 
Realplex4 thermal cycler (Eppendorf; Westbury, NY).  All samples were done in 
triplicate.  Ct values were generated for each reaction and melting curve analysis 
was done to ensure only one product was amplified in each reaction.  Changes in 
gene expression were analyzed by the ΔΔCt method using the two closest Ct 
values from each set of triplicates, as long as they were within one amplification 
cycle.  These values were averaged to generate ΔCt values, which were in turn 
used to generate the ΔΔCt as described previously (Cornett et al. 2011). Figure 5 
is an outline of the Q-PCR tissue preparation, protocol, and data analysis. 
   
Figure 5: Outline of Real Time PCR Protocol 
 
Figure 5: Outline of the real time PCR analysis. 
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WESTERN BLOTTING: 
Brain tissue was removed from VC from WT and RD mice (n = 48) at different 
development times (postnatal days 14, 28, and 49). Tissue was vigorously 
triturated in ice-cold lysis buffer (50 mM Tris-HCl [pH 8.0], 0.15 M NaCl, 1% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate), 
centrifuged at 10,000 g for 10 min to remove debris, and the supernatant was 
stored at -80° C.  Protein concentrations in the lysates were determined using a 
Pierce® BCA Protein Assay kit (Thermo Fisher; Waltham, MA) and 10 ug 
(BDNF/NT-3 analysis) and 12-23 ug (NT-3 analysis) total protein were subjected 
to SDS-PAGE (Bolt 4-12% gradient resolving gel; Life Technologies).  Resolved 
proteins were transferred to Immobilon-P membranes (Millipore; Billerica, MA). 
The Immobilon was blocked for 1 hr (room temperature, on an orbital shaker set 
to 50 rpm) in TBS-Tween (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween 
20) containing 3% non-fat milk.  Polyclonal rabbit antibodies to BDNF (Abcam; 
Cambridge, MA), NT3 (Thermo Fisher), and β-actin (Thermo Fisher) were used 
for the blotting.  Antibodies were diluted into the blocking solution (1:500 for anti-
BDNF, 1:1000 for anti-NT3, and 1:2000 for anti-β-actin) and incubated overnight 
at room temperature on an orbital shaker (50 rpm). The blot was then washed 
three times (3 minutes each) with TBS-Tween (20 ml each wash) and blocked 
again for 30 minutes. Anti-rabbit IgG conjugated to alkaline phosphatase 
(Promega; Madison, WI) was diluted 1:2500 into the blocking solution and 
incubated for 1.5 hr at room temperature (50 rpm on orbital shaker). The blot was 
washed twice (3 minutes each) with TBS-Tween (20ml each wash), and once (3 
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min) with western blot substrate buffer (0.1 M Tris-HCl [pH 9.5], 0.1 M NaCl, 
5mM MgCl2).    
 
DATA & STATISTICAL ANALYSIS: 
SPSS for Windows (Version 16) was used for analysis of mRNA expression 
using a t-test with age as the between-subject variable interpreting any significant 
factor interactions and for all tests, p<0.05 was considered statistically significant 
(Jarvinen et al., 2010). The analysis was used to determine differences in gene 
expression from RD and WT brain lysates. 
 
Western Blot analysis was performed using Image J software from the National 
Institute of Health (NIH). To perform Image J analysis, we opened the image of 
the blot in Image J and, using the triangle tool, we drew a border around each 
band and selected analyze. This was carried out for each band on each western 
blot. The straight-line tool was used to connect the base of each peak and then 
to remove background between each band. Each peak was then highlighted, and 
the area of the peak appeared in a separate window. An analysis of the percent 
saturation peaks was then obtained. This information was copied and pasted into 
a Microsoft Excel document. These data were normalized against a b-actin band 
and then t-tests were performed for statistical analysis. 
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RESULTS: 
To begin, the difference between WT mice RD mice was established as 
described previously in the methods section. Figure 6 shows the results of this 
test. By PND 49, the RD mice showed no evidence of normal visual activity. 
 
Figure 6: Verification of Retinal Degeneration in Pde6b- Transgenic Mice 
 
 
 
Figure 6: Verification of retinal degeneration in RD mice. To determine loss of 
vision at days 21, 28, 35, 42, and 49, the RD and WT mice were lowered onto 
sand paper of varying grade (smooth, medium, and coarse). Mice were held by 
the tail and lowered down to a surface of sandpaper, where they would splay 
legs (or not) before impact. Mice with normal visual activity would splay legs 
while mice with defective vision would not. ** Significance was determined by t-
test, p < 0.05. 
 
To examine molecular events that might be driving remodeling, we looked at 
mRNA expression of the four neurotrophins in the VC before (PND 14), during 
(PND 28), and after (PND 49) the onset of blindness. In Figure 7 we see the 
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analysis of BDNF mRNA in RD and WT mice. In WT mice, BDNF mRNA levels 
steadily increased between PND 14 and 49, with a very steep increase between 
PND 28 and 49. This increase was not seen in RD mice, which actually show a 
decrease in BDNF mRNA at PND 49. There was a significantly higher (p < 0.05) 
level of BDNF mRNA observed in the VC of WT mice at PND 49.  
 
Figure 7: Expression of BDNF mRNA in RD Mice 
 
 
Figure 7: Analysis of BDNF mRNA expression in wild type and retinal 
degeneration mice at postnatal days 14, 28, and 49. Changes in gene expression 
were analyzed by the ΔΔCt method using the two closest Ct values from each 
set of triplicates, as long as they were within one amplification cycle.  These 
values were averaged to generate ΔCt values, which were in turn used to 
generate the ΔΔCt. Expression in RD was normalized to WT BDNF expression at 
PND 14. **Significance was determined by t-test, p < 0.05. 
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Figure 8 shows that in WT mice, NT-3 mRNA levels decreased between PND 14 
and 49, but this decrease was not seen in RD mice, who showed steady or 
increasing NT-3 mRNA expression. There was a significantly higher (p < 0.05) 
level of NT-3 mRNA observed in the VC of RD mice at PND 49.  
 
Figure 8: Expression of NT-3 mRNA in RD Mice 
 
 
Figure 8: Analysis of NT-3 mRNA expression in wild type and retinal 
degeneration mice at postnatal days 14, 28, and 49. Changes in gene expression 
were analyzed by the ΔΔCt method using the two closest Ct values from each 
set of triplicates, as long as they were within one amplification cycle.  These 
values were averaged to generate ΔCt values, which were in turn used to 
generate the ΔΔCt. Expression in RD was normalized to WT NT-3 expression at 
PND 14. **Significance was determined by t-test, p < 0.05. 
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Figure 9 shows the analysis of NGF mRNA in RD and WT mice. In WT mice, 
NGF mRNA levels steadily decreased between PND 14 and 49. In RD mice, this 
trend is delayed. In RD mice, the decrease does not occur until after PND 28, 
resulting in a significant (p < 0.05) increase in RD vs. WT NGF mRNA at PND 28. 
This is an increase in NGF mRNA expression in Pde6b- mice compared to WT 
NGF mRNA expression.  
 
Figure 9: Expression of NGF mRNA in RD Mice 
 
 
 
Figure 9: Analysis of NGF mRNA expression in wild type and retinal 
degeneration mice at postnatal days 14, 28, and 49. Changes in gene expression 
were analyzed by the ΔΔCt method using the two closest Ct values from each 
set of triplicates, as long as they were within one amplification cycle.  These 
values were averaged to generate ΔCt values, which were in turn used to 
generate the ΔΔCt. Expression in RD mice was normalized to WT NGF 
expression at PND 14. **Significance was determined by t-test, p < 0.05. 
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Figure 10 shows the analysis of NT-4 mRNA in Pde6b- and WT mice. In both WT 
and Pde6b- mice, there is a steady increase in NT-4 mRNA expression from 
PND 14 to 49. This resulted in no significant (p < 0.05) differences in RD vs. WT 
NT-4 mRNA. 
 
Figure 10: Expression of NT-4 mRNA in RD Mice 
 
 
Figure 10: Analysis of NT-4 mRNA expression in wild type and retinal 
degeneration mice at postnatal days 14, 28, and 49. Changes in gene expression 
were analyzed by the ΔΔCt method using the two closest Ct values from each 
set of triplicates, as long as they were within one amplification cycle.  These 
values were averaged to generate ΔCt values, which were in turn used to 
generate the ΔΔCt. Expression in RD was normalized to WT NT-4 expression at 
PND 14. **Significance was determined by t-test, p < 0.05. 
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Figure 11 shows the combined Q-PCR results for the four neurotrophins and 
highlights significant differences in expression that were found at PND 28 for 
NGF, and PND 49 for NT-3 and BDNF. Significance is marked by ** where p < 
0.05.  
Figure 11: mRNA Expression of Neurotrophins in RD Mice 
 
Figure 11: Q-PCR results for BDNF, NGF, NT-3, and NT-4. Graph displays 
mRNA expression for neurotrophins BDNF, NGF, NT-3, and NT-4 at PND 14, 29, 
and 49 in RD mice. Changes in gene expression were analyzed by the ΔΔCt 
method using the two closest Ct values from each set of triplicates, as long as 
they were within one amplification cycle. These values were averaged to 
generate ΔCt values, which were in turn used to generate the ΔΔCt. Expression 
was normalized to WT at PND 14.  **Significance was determined by t-test, p < 
0.05. 
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We next decided to investigate if neurotrophin protein levels matched the 
changes in mRNA levels that were seen for BDNF and NT-3. We used western 
blotting to detect the proteins, quantified the results with Image J, and normalized 
the results to the b-actin control. Because the pro- and mature forms of these 
neurotrophins can elicit dramatically different biological efforts, we analyzed the 
levels of both their pro- and mature forms.  
 
Figure 12 shows the combined results of all BDNF western blot data. The RD 
mice showed decreased levels of both pro- and mature forms of BDNF at both 
PND 14 and 49. The decrease seen at PND 49 is consistent with mRNA 
analysis, in which the RD mice had a much lower expression level at PND 49.  
 
Figure 13 shows the combined results of all NT-3 western blot data. No 
differences were observed in pro-NT-3 levels at any postnatal age. However, at 
PND 14, the RD mice showed a higher level of mature NT-3.  
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Figure 12: Combined Western Blot Data for pro- and Mature BDNF 
 
 
Figure 12: Combined western blot data for pro- and mature BDNF. Panel A 
shows a B-actin sample western blot containing 3 WT samples and 3 RD 
samples. Panel B shows a pro-BDNF sample western blot containing 3 WT 
samples and 3 RD samples. Panel C shows a BDNF sample western blot 
containing 3 WT samples and 3 RD samples. Panel D illustrates all pro-BDNF 
results at PND 14, 28, and 49 in WT and RD mice. Panel E is a graph of all 
mature BDNF results at PND 14, 28, and 49 in WT and RD mice. **Significance 
p < 0.05. 
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Figure 13: Combined Western Blot Data for pro- and Mature NT-3 
 
Figure 13: Combined western blot data for pro- and mature NT-3. Panel A 
shows a B-actin sample western blot containing 3 WT samples and 3 RD 
samples. Panel B shows a pro-NT-3 sample western blot containing 3 WT 
samples and 3 RD samples. Panel C shows a mature NT-3 sample western blot 
containing 3 WT samples and 3 RD samples. Panel D illustrates all pro-NT-3 
results at PND 14, 28, and 49 in WT and RD mice. Panel E is a graph of all 
mature NT-3 results at PND 14, 28, and 49 in WT and RD mice. **Significance p 
< 0.05. 
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DISCUSSION: 
The goal of this study was to investigate neurotrophin levels in the brain under 
traumatic circumstances. The first step to accomplish this was to identify a model 
of TBI. RD mice homozygous for a loss of function mutation in the Pde6b gene 
could provide a good model as they lose vision in early postnatal development. 
Vision loss was verified through a simple test, wherein at days 21, 28, 35, 42, 
and 49, the RD and WT mice were lowered onto sand paper of varying grade 
(smooth, medium, and coarse) where they would splay legs (or not) before 
impact. WT mice would splay legs while mutant mice would not. Once verification 
of vision loss was completed, we investigated expression of neurotrophins whose 
production and processing could be critical to events in TBI. It is known that 
protein production can be regulated at several points during gene expression. To 
determine whether neurotrophin production is regulated at the transcription, 
translation, or post-translational level we examined mRNA and protein levels for 
these proteins in RD and WT mice at various PND time points. Quantitative real-
time PCR (Q-PCR) was utilized to analyze the mRNA levels of BDNF, NT-3, NT-
4, and NGF in VC tissue samples. Changes in gene expression were analyzed 
by the ΔΔCt method using the two closest Ct values from each set of triplicates, 
as long as they were within one amplification cycle.  These values were 
averaged to generate ΔCt values, which were in turn used to generate the ΔΔCt 
as described previously (Jarvinen et al., 2010). Following the mRNA analysis 
using Q-PCR, western blotting was to examine protein expression. The protein 
level of both pro- and mature neurotrophins, BDNF and NT-3 was examined. 
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Protein expression does not always directly correlate with the amount of mRNA 
present, which is why both levels (mRNA and protein) were assessed.  
 
VISUAL IMPAIRMENT ALTERS BDNF LEVELS 
Because neurotrophins are implicated in cell differentiation, proliferation, survival, 
and cell death, an overarching hypothesis that in times of traumatic brain injury, 
the level of mature neurotrophins would increase, leading to proliferation. 
Specifically within the VC in this study, it could also be hypothesized that an 
increase in pro-neurotrophins could be seen, leading to cell death, as well as a 
decrease in mature neurotrophins because of the damage occurring to the VC 
during vision loss. Specifically, for BDNF, the latter was seen. BDNF mRNA 
levels steadily increased in WT mice between PND 14 and 49, with a very steep 
increase between PND 28 and 49. This increase was not seen in RD mice, which 
actually show a decrease in BDNF mRNA at PND 49. There was a significantly 
higher (p < 0.05) level of BDNF mRNA observed in the VC of WT mice at PND 
49 compared to the RD mice. Alongside the mRNA data, the protein analysis 
confirms a decrease in both pro- and mature BDNF levels in RD mice during the 
process of retinal degeneration. This could reflect the role of mature BDNF in 
establishing neural connectivity (Bung Hu and Cohen-Cory, 2005). In the visual 
cortex of RD mice, there is no need for new neural connections, because the 
vision has been lost by PND 49. The overall lower amount of pro- and mature 
BDNF at both PND 14 and PND 49 in RD mice could be significant as sensory 
deprivation could be starting by PND 14 (Jarvinen et al., 2010; Cornett et al., 
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2011). In WT mice, the difference in BDNF protein levels at PND 14 to PND 49 
could be explained by the developing brain; more neural connections would be 
established during development as compared to PND 49 in the RD mice when all 
vision has been lost. 
 
NT-3 LEVELS ARE AFFECTED BY VISUAL IMPAIRMENT 
Investigation into NT-3 expression revealed interesting and contradictory results. 
First, Q-PCR results showed that NT-3 mRNA levels remained high during PND 
14-49, in contrast to WT levels, which decreased. These results were 
contradicted by the protein data produced by western blot analyses. In Figure 
13D, no significant differences were seen in pro-NT3 levels between RD and WT 
mice at any postnatal time period (Figure 13E). However, at PND 14, there is a 
significant increase in mature NT-3 in RD mice compared to WT mice.  A 
potential explanation for this could be due to the levels of PCs available for 
processing proproteins to mature proteins in RD mice during this timeframe. The 
PCs, PCSK9 and furin, have both been shown to increase at the level of mRNA 
during postnatal weeks 1-3 in RD mice (Jarvinen et al., 2010). Because NT-3 is 
expressed in the VC during development and visual impairment, and based on 
the level of the aforementioned PCs, the amount of mature NT-3 could go up at 
PND 14 compared to WT (Jarvinen et al., 2010; Cornett et al., 2011). This could 
make sense considering the role that mature NT-3 plays in neuronal survival 
(Chao et al., 2006). With sensory deprivation beginning around PND 14, 
production of mature NT-3 could be induced to counteract, at least short-term, 
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neuronal death. Another possible reason for the discrepancy between the NT-3 
mRNA and protein levels could be due to an increased stress response causing 
an increase in mRNA, but for the same reason, a stress response, causing the 
translation into protein being stopped for conservation of resources in the dying 
VC. While there is currently no documentation of neurotrophin expression being 
regulated at the level of translation, this is a commonly used regulatory 
mechanism. A well-studied example of regulation of at the translational level is 
the transferrin receptor. This regulation is dictated by several things. For 
example, the level of cellular stress, amount of available iron, and regulatory 
proteins all dictate translation of the transferrin receptor mRNA (Theil, 1990). Like 
the transferrin receptor, NT-3 could also be regulated at this stage.  
 
FUTURE EXPERIMENTATION: 
Future experimentation of protein analysis for NGF would provide a more 
comprehensive analysis of the neurotrophins. This could be done like the BDNF 
and NT-3 analysis utilizing western blotting and Image J. The key time point for 
this analysis could be PND 28, where RD mice show higher NGF mRNA levels 
than WT mice (Figure 9).  
 
Further experimentation utilizing fluorescence-activated cell sorting (FACS) could 
provide insight into levels of neurotrophin mRNA and protein levels in specific cell 
types. The mice selected for this study have fluorescently tagged astrocytes, 
neurons, and oligodendrocytes. Once separated by FACS, the samples can be 
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processed like all other samples for this project and subjected Q-PCR and 
Western blotting. This information would provide vital knowledge, because each 
cell-type has different functions that require different growth factors. This testing 
could give specific results showing which neurotrophins are most pertinent in 
specific cell types. Identifying specific neurotrophin information for specific cell 
types may provide future therapeutic options targeting neurotrophins.  
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APENDICES: 
1) PND 14 PROTEIN ANALYSIS T-TEST 
T-Test 
 
Notes 
Output Created 01-OCT-2017 20:09:08 
Comments  
Input Data D:\Laptop Backup 0621 
2017\Research\nsf data\Stats 
analysis\Jarvinen PND 14 
neurotrophin protein raw data 
10012017.sav 
Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
7 
Missing Value Handling Definition of Missing User defined missing values 
are treated as missing. 
Cases Used Statistics for each analysis 
are based on the cases with 
no missing or out-of-range 
data for any variable in the 
analysis. 
Syntax T-TEST 
GROUPS=Genotype(1 2) 
  /MISSING=ANALYSIS 
  /VARIABLES=BActin BDNF 
proBDNF NT3 proNT3 
  /CRITERIA=CI(.95). 
Resources Processor Time 00:00:00.03 
Elapsed Time 00:00:00.05 
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Group Statistics 
 Genotype N Mean Std. Deviation Std. Error Mean 
BActin Wild-type 3 1.0350 .03730 .02153 
rd 3 1.0323 .09437 .05448 
BDNF Wild-type 3 1.1224 .13411 .07743 
rd 3 .8944 .11462 .06618 
proBDNF Wild-type 3 1.2275 .19964 .11526 
rd 3 .5964 .18367 .10604 
NT3 Wild-type 3 .8549 .13103 .07565 
rd 3 1.1960 .01642 .00948 
proNT3 Wild-type 3 .8299 .16486 .09518 
rd 3 .7286 .15319 .08845 
 
 
Independent Samples Test 
 
Levene's Test for Equality of 
Variances 
t-test for Equality of 
Means 
F Sig. t df 
BActin Equal variances assumed 1.356 .309 .046 4 
Equal variances not 
assumed 
  .046 2.610 
BDNF Equal variances assumed .121 .745 2.239 4 
Equal variances not 
assumed 
  2.239 3.905 
proBDNF Equal variances assumed .112 .755 4.030 4 
Equal variances not 
assumed 
  4.030 3.972 
NT3 Equal variances assumed 6.822 .059 -4.474 4 
Equal variances not 
assumed 
  -4.474 2.063 
proNT3 Equal variances assumed .005 .948 .780 4 
Equal variances not 
assumed 
  .780 3.979 
 
Independent Samples Test 
 t-test for Equality of Means 
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Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower 
BActin Equal variances assumed .966 .00269 .05858 -.15997 
Equal variances not 
assumed 
.967 .00269 .05858 -.20055 
BDNF Equal variances assumed .089 .22801 .10186 -.05479 
Equal variances not 
assumed 
.090 .22801 .10186 -.05752 
proBDNF Equal variances assumed .016 .63113 .15662 .19628 
Equal variances not 
assumed 
.016 .63113 .15662 .19509 
NT3 Equal variances assumed .011 -.34112 .07624 -.55281 
Equal variances not 
assumed 
.044 -.34112 .07624 -.65979 
proNT3 Equal variances assumed .479 .10139 .12993 -.25936 
Equal variances not 
assumed 
.479 .10139 .12993 -.26013 
 
Independent Samples Test 
 
t-test for Equality of Means 
95% Confidence Interval of the 
Difference 
Upper 
BActin Equal variances assumed .16534 
Equal variances not assumed .20592 
BDNF Equal variances assumed .51081 
Equal variances not assumed .51354 
proBDNF Equal variances assumed 1.06599 
Equal variances not assumed 1.06718 
NT3 Equal variances assumed -.12943 
Equal variances not assumed -.02245 
proNT3 Equal variances assumed .46214 
Equal variances not assumed .46290 
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2) PND 28 PROTEIN ANALYSIS T-TEST: 
T-Test 
Notes 
Output Created 01-OCT-2017 20:11:24 
Comments  
Input Data D:\Laptop Backup 0621 
2017\Research\nsf data\Stats 
analysis\Jarvinen PND 28 
neurotrophin protein raw data 
10012017.sav 
Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
6 
Missing Value Handling Definition of Missing User defined missing values 
are treated as missing. 
Cases Used Statistics for each analysis 
are based on the cases with 
no missing or out-of-range 
data for any variable in the 
analysis. 
Syntax T-TEST 
GROUPS=Genotype(1 2) 
  /MISSING=ANALYSIS 
  /VARIABLES=BActin BDNF 
proBDNF NT3 proNT3 
  /CRITERIA=CI(.95). 
Resources Processor Time 00:00:00.00 
Elapsed Time 00:00:00.01 
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Group Statistics 
 Genotype N Mean Std. Deviation Std. Error Mean 
BActin Wild-type 3 1.0799 .06924 .03998 
RD 3 1.1994 .20318 .11731 
BDNF Wild-type 3 1.1818 .17336 .10009 
RD 3 1.1195 .43342 .25024 
proBDNF Wild-type 3 .8050 .31480 .18175 
RD 3 1.0295 .31168 .17995 
NT3 Wild-type 3 1.1217 .16826 .09715 
RD 3 1.1270 .25532 .14741 
proNT3 Wild-type 3 1.4012 .34772 .20076 
RD 3 1.1800 .24363 .14066 
 
 
Independent Samples Test 
 
Levene's Test for Equality of 
Variances 
t-test for Equality of 
Means 
F Sig. t df 
BActin Equal variances assumed 1.915 .239 -.964 4 
Equal variances not 
assumed 
  -.964 2.458 
BDNF Equal variances assumed 2.827 .168 .231 4 
Equal variances not 
assumed 
  .231 2.624 
proBDNF Equal variances assumed .019 .898 -.878 4 
Equal variances not 
assumed 
  -.878 4.000 
NT3 Equal variances assumed .318 .603 -.030 4 
Equal variances not 
assumed 
  -.030 3.462 
proNT3 Equal variances assumed .942 .387 .902 4 
Equal variances not 
assumed 
  .902 3.582 
3)  
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Independent Samples Test 
 
t-test for Equality of Means 
Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower 
BActin Equal variances assumed .390 -.11949 .12393 -.46358 
Equal variances not 
assumed 
.420 -.11949 .12393 -.56793 
BDNF Equal variances assumed .829 .06224 .26951 -.68604 
Equal variances not 
assumed 
.834 .06224 .26951 -.86937 
proBDNF Equal variances assumed .429 -.22457 .25576 -.93468 
Equal variances not 
assumed 
.430 -.22457 .25576 -.93471 
NT3 Equal variances assumed .978 -.00527 .17654 -.49543 
Equal variances not 
assumed 
.978 -.00527 .17654 -.52702 
proNT3 Equal variances assumed .418 .22113 .24513 -.45946 
Equal variances not 
assumed 
.424 .22113 .24513 -.49193 
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Independent Samples Test 
 
t-test for Equality of Means 
95% Confidence Interval of the 
Difference 
Upper 
BActin Equal variances assumed .22460 
Equal variances not assumed .32894 
BDNF Equal variances assumed .81052 
Equal variances not assumed .99385 
proBDNF Equal variances assumed .48554 
Equal variances not assumed .48557 
NT3 Equal variances assumed .48489 
Equal variances not assumed .51647 
proNT3 Equal variances assumed .90173 
Equal variances not assumed .93419 
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3) PND 49 PROTEIN ANALYSIS T-TEST: 
 
t-test 
 
Notes 
Output Created 01-OCT-2017 20:12:34 
Comments  
Input Data D:\Laptop Backup 0621 
2017\Research\nsf data\Stats 
analysis\Jarvinen PND 49 
neurotrophin protein raw data 
10012017.sav 
Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
7 
Missing Value Handling Definition of Missing User defined missing values 
are treated as missing. 
Cases Used Statistics for each analysis 
are based on the cases with 
no missing or out-of-range 
data for any variable in the 
analysis. 
Syntax T-TEST 
GROUPS=Genotype(1 2) 
  /MISSING=ANALYSIS 
  /VARIABLES=BActin BDNF 
proBDNF NT3 proNT3 
  /CRITERIA=CI(.95). 
Resources Processor Time 00:00:00.00 
Elapsed Time 00:00:00.01 
 
 
[DataSet1] D:\Laptop Backup 0621 2017\Research\nsf data\Stats analysis\Jarvinen PND 
49 neurotrophin protein raw data 10012017.sav 
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Group Statistics 
 Genotype N Mean Std. Deviation Std. Error Mean 
BActin Wild-type 3 .9126 .10083 .05822 
RD 3 1.1299 .11834 .06832 
BDNF Wild-type 3 1.2723 .37975 .21925 
RD 3 .5147 .44092 .25457 
proBDNF Wild-type 3 1.8351 .25619 .14791 
RD 3 1.2003 .27694 .15989 
NT3 Wild-type 3 .7984 .17707 .10223 
RD 3 .7122 .06870 .03966 
proNT3 Wild-type 3 .8210 .16845 .09725 
RD 3 .7054 .04761 .02749 
 
 
Independent Samples Test 
 
Levene's Test for Equality of 
Variances 
t-test for Equality of 
Means 
F Sig. t df 
BActin Equal variances assumed .081 .790 -2.421 4 
Equal variances not 
assumed 
  -2.421 3.902 
BDNF Equal variances assumed .055 .826 2.255 4 
Equal variances not 
assumed 
  2.255 3.914 
proBDNF Equal variances assumed .068 .807 2.914 4 
Equal variances not 
assumed 
  2.914 3.976 
NT3 Equal variances assumed 4.102 .113 .786 4 
Equal variances not 
assumed 
  .786 2.589 
proNT3 Equal variances assumed 2.821 .168 1.144 4 
Equal variances not 
assumed 
  1.144 2.318 
 
Independent Samples Test 
 t-test for Equality of Means 
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Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower 
BActin Equal variances assumed .073 -.21729 .08976 -.46651 
Equal variances not 
assumed 
.074 -.21729 .08976 -.46900 
BDNF Equal variances assumed .087 .75764 .33597 -.17516 
Equal variances not 
assumed 
.089 .75764 .33597 -.18330 
proBDNF Equal variances assumed .043 .63477 .21781 .03002 
Equal variances not 
assumed 
.044 .63477 .21781 .02858 
NT3 Equal variances assumed .476 .08617 .10965 -.21827 
Equal variances not 
assumed 
.497 .08617 .10965 -.29635 
proNT3 Equal variances assumed .316 .11561 .10106 -.16499 
Equal variances not 
assumed 
.357 .11561 .10106 -.26685 
 
Independent Samples Test 
 
t-test for Equality of Means 
95% Confidence Interval of the 
Difference 
Upper 
BActin Equal variances assumed .03193 
Equal variances not assumed .03443 
BDNF Equal variances assumed 1.69044 
Equal variances not assumed 1.69858 
proBDNF Equal variances assumed 1.23952 
Equal variances not assumed 1.24097 
NT3 Equal variances assumed .39062 
Equal variances not assumed .46870 
proNT3 Equal variances assumed .39620 
Equal variances not assumed .49806 
 
 
 
